Insulet Appoints New CFO: Ana Maria Chadwick

Share This Post

Key Highlights

  • Ana Maria Chadwick appointed as Executive VP, CFO, and Treasurer, effective April 22, 2024.
  • Chadwick brings 30 years of experience from roles at Pitney Bowes and GE, showcasing significant financial and operational leadership.
  • Known for her strategic insight and collaborative leadership, enhancing Insulet’s mission to simplify life for people with diabetes.

Source: Business Wire

Notable Quotes

  • “I look forward to working with Jim and the talented team to build on Insulet’s strong financial foundation, further driving growth, profitability, and value for shareholders.” – Ana Maria Chadwick, Incoming CFO at Insulet Corporation
  • “She is an experienced public company CFO… Ana is known for her insight, intellectual agility, and compelling and collaborative leadership.” – Jim Hollingshead, President and CEO at Insulet Corporation

SoHC's Take

Ana Maria Chadwick’s appointment as CFO of Insulet Corporation marks a pivotal moment in the company’s journey. Her rich background in financial and operational leadership at companies like Pitney Bowes and GE not only underscores her capability to drive financial growth but also highlights her commitment to innovative and strategic leadership. Chadwick’s role in transforming Pitney Bowes and her extensive tenure at GE, coupled with her involvement in initiatives like LiveGirl, Inc., reflect a deep-seated commitment to fostering growth, efficiency, and meaningful social impact.

This strategic hire comes at a time when Insulet, a pioneer in tubeless insulin pump technology, seeks to expand its reach and enhance its product offerings to meet the growing demands of the diabetes community. Chadwick’s leadership is expected to fortify Insulet’s financial foundations, enabling the company to continue its trajectory of innovation and market expansion. Her appointment is a testament to Insulet’s dedication to attracting leaders who not only bring vast experience but also a shared vision for the future of diabetes care.

More To Explore

Total
0
Share